ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CLGN
CUPR (21) RGNT (31) HSCS (38) LFWD (32) ⌘ Pro Terminal →

CollPlant Biotechnologies Ltd (CLGN) — RQD Stock Rating Cockpit

$4.14 -6.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.09

CollPlant Biotechnologies Ltd (CLGN) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $11.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLGN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.14 (-6.02% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLGN ranks #450 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLGN compare to CUPR and RGNT in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M) and RGNT (Regentis Biomaterials Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.6M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLGN?
▼

Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.09 (-1.27%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (9)SEC (11)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$24 Bull$4 Base$3 Bear
📬 FREE CLGN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLGN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY CLGN SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$3.91-0.8% Next Q
Q2 (-2Q)
36
Grade E$3.88+0.5% Next Q
Q3 (-1Q)
38
Grade E$3.90+6.2% Next Q
Current
41
Grade D-$4.14-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLGN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLGN currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.74) and Max Pain ($4.35) forces dealer call-delta covering toward $24.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLGN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLGN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
54.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE7% OF RANGE
L: $3$4.14H: $23
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on CLGN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 64.8% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CLGN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLGN)

  • ✓Walkthrough of CLGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.96%🛡️ HOLDING TREND SUPPORT
2026-11-03O $4.40H $4.40L $4.14C $4.14VOL 44.3K
RES: $12.56SUP: $3.57SMA50: $3.74SMA200: $5.00
$17.78$13.68$9.57$5.47$1.37RES $12.56SUP $3.57$4.142026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLGN Butterfly Map → + Track CLGN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +360.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLGN)

Health Care Rank #450 of 1015 ⚔️ CUPR vs CLGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLGN vs. CUPR, RGNT, HSCS, LFWD)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, CollPlant Biotechnologies Ltd (CLGN) ranks #450 by composite RQD confidence (41/100, grade D-) and #876 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, CLGN leads on earnings valuation at N/A trailing P/E, while CLGN leads on capital efficiency and profitability with -35.0% ROIC and 64.8% gross margin. CLGN currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLGN ACTIVE
CollPlant Biotechnologies Ltd
D- 41/100 — 64.8% -35.0% -6.02% $11.9M Benchmark Subject
CUPR
Cuprina Holdings (Cayman) Limited (Class A)
E 21/100 — -1.3% -35.0% -3.80% $13.5M /cupr-vs-clgn →
RGNT
Regentis Biomaterials Ltd.
E 31/100 — — -35.0% +0.74% $9.6M /rgnt-vs-clgn →
HSCS
HeartSciences Inc.
D- 38/100 — 59.1% -35.0% -8.31% $16.0M /hscs-vs-clgn →
LFWD
Lifeward Ltd.
E 32/100 — 96.0% -35.0% +0.71% $16.9M /lfwd-vs-clgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001631487 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported GAAP revenue of $2.4M (+360.4% vs. FY2024 revenue of $515.0K , and -78.4% cumulative change since FY2023) , GAAP net income of -$11.5M, operating cash flow of -$9.4M, and free cash flow of -$9.4M (+35.2% YoY). On the balance sheet, CLGN closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.4M -$11.5M -$9.4M -$9.4M $10.8M —
FY2024 (FY) 2024-12-31 $515.0K -$16.6M -$14.1M -$14.6M $18.7M —
FY2023 (FY) 2023-12-31 $11.0M -$7.0M -$2.8M -$2.8M — —

3. CLGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.14 (-6.02% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CLGN ranks #450 in composite RQD confidence.

How does CLGN compare to CUPR and RGNT in the Health Care sector?

Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $13.5M) and RGNT (Regentis Biomaterials Ltd.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $9.6M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLGN?

Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLGN trading relative to its 50-day, 200-day, and 52-week technical levels?

CLGN last traded at $4.14 (-6.02% on volume of 44,258 shares), positioning the stock +10.70% above its 50-day simple moving average ($3.74) and -17.20% below its 200-day simple moving average ($5.00). Across its 52-week range of $2.64 to $22.90, CLGN sits at the 7.4% percentile with a 14-day RSI of 54.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.62 to $4.66).

Direct Sub-Reports: CLGN RQD Cockpit CLGN 12M Forecast CLGN Earnings & Move CLGN Dividends & DRIP CLGN Insiders & 13F CLGN Whale Options CLGN Profit Sankey CLGN News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CLGN — CollPlant Biotechnologies Ltd: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

CollPlant Biotechnologies Ltd (CLGN) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.14 (-6.02% 1D, market capitalization $11.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 64.8%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

CollPlant Biotechnologies Ltd (CLGN) is listed on NASDAQ and classified under the Health Care sector and Industrial Specialties industry,. Reported revenue was $2.4M in FY 2025, $0.5M in FY 2024, and $11.0M in FY 2023. Gross margin is reported at 64.8%, while operating margin is -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported $2.4M in annual revenue (up from $515.0K in FY2024, +360.4% YoY) and -$11.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($11.0M revenue, -$7.0M net income) through FY2025, CLGN scaled operating cash flow to -$9.4M and free cash flow to -$9.4M, backed by $10.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.64 – $22.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector-level information is the classification as Health Care / Industrial Specialties. Investors should treat the absence of mapped supply-chain links as a gap in the analysis rather than evidence of independence.

  • Key Question #1: Can CLGN sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.4M and free cash flow of -$9.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLGN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLGN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CollPlant Biotechnologies Ltd (CLGN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLGN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLGN Bull vs. Bear Conversation Board — What's Your Call at $4.14?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLGN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLGN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $5.13 (+23.9%)
📌 Pinned Debate

Forensic balance sheet pillar (11/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest component of the rating and gross margin is 64.8%

Here is why I am bullish on CLGN here at $4.14: Forensic balance sheet pillar (11/20, Altman Z 2.5, Debt/Equity 0.5) is the strongest component of the rating and gross margin is 64.8%.. Compare CLGN's -60.0% operating margin and -35.0% ROIC against the rest of Industrial Specialties. As long as cash conversion holds up, dips toward $3.93 are getting bought.

VolSurface_Trader 🐂 BULL

Both sides have a point here — CLGN's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.39 (-18.1%)
Spot @ $4.14

Revenue fell from $11.0M to $2.4M while operating losses persisted at -$11.5M and ROIC sits at -35%, alongside dilution signals from a

Revenue fell from $11.0M to $2.4M while operating losses persisted at -$11.5M and ROIC sits at -35%, alongside dilution signals from a $3.7M private placement and exhausted offering capacity.. Look at the math on CLGN: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Industrial Specialties demand softens. I'd wait for a retest of $3.64 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%